Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last --
Change Today 0.00 / 0.00%
Volume 0.0
JNJ On Other Exchanges
Symbol
Exchange
New York
Xetra
Mexico
Sao Paulo
Bogota
All times are local (Market data is delayed by at least 15 minutes).

johnson & johnson (JNJ) Snapshot

Open
--
Previous Close
$189,300
Day High
--
Day Low
--
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
--
Average Volume 10 Days
0.0
EPS TTM
--
Shares Outstanding
2.8B
EX-Date
05/21/15
P/E TM
--
Dividend
$3.00
Dividend Yield
3.12%
Current Stock Chart for JOHNSON & JOHNSON (JNJ)

johnson & johnson (JNJ) Details

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON’S brand name; oral care products under the LISTERINE brand name; skin care products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON’S Adult, LE PETITE MARSEILLAIS, LUBRIDERM, NEUTROGENA, and RoC brand names; women’s health products, such as sanitary pads under the STAYFREE and CAREFREE, and o.b. tampon brand names; wound care products, including adhesive bandages and first aid products under the BAND-AID and NEOSPORIN brand names; and nutritional products comprising no calorie sweetener under the SPLENDA brand name. This segment also offers over-the-counter medicines, including acetaminophen products under the TYLENOL brand name; cold, flu, and allergy products under the SUDAFED brand name; allergy products under the BENADRYL and ZYRTEC brand names; ibuprofen products under the MOTRIN IB brand name; and heartburn products under the PEPCID brand name. The Pharmaceutical segment provides various products in the areas of immunology, infectious diseases, neuroscience, oncology, and cardiovascular and metabolic diseases. The Medical Devices segment offers orthopaedic, and trauma and neurological products; general surgery, and biosurgical and energy products; products to treat cardiovascular disease; infection prevention products; diagnostics products; blood glucose monitoring and insulin delivery products; and disposable contact lenses. The company distributes its products to general public, retail outlets and distributors, wholesalers, hospitals, and health care professionals for prescription use in the professional fields by physicians, nurses, hospitals, and clinics. Johnson & Johnson was founded in 1885 and is based in New Brunswick, New Jersey.

126,500 Employees
Last Reported Date: 02/24/15
Founded in 1885

johnson & johnson (JNJ) Top Compensated Officers

Chairman, Chief Executive Officer, Chairman o...
Total Annual Compensation: $1.5M
Chief Financial Officer, Vice President of Fi...
Total Annual Compensation: $878.1K
Worldwide Chairman of Pharmaceuticals, Chief ...
Total Annual Compensation: $1.1M
Group Worldwide Chairman and Member of Execut...
Total Annual Compensation: $841.3K
Vice President, General Counsel and Member of...
Total Annual Compensation: $591.3K
Compensation as of Fiscal Year 2014.

johnson & johnson (JNJ) Key Developments

Johnson & Johnson Declares Quarterly Dividend, Payable on June 9, 2015

Johnson & Johnson announced that its Board of Directors has declared a 7.1% increase in the quarterly dividend rate, from $0.70 per share to $0.75 per share. At the new rate, the indicated dividend on an annual basis is $3.00 per share compared to the previous rate of $2.80 per share. The next quarterly dividend is payable on June 9, 2015 to shareholders of record as of the close of business on May 26, 2015. The ex-dividend date is May 21, 2015.

J&J Launches Invokana in India

Johnson & Johnson has announced the launch of its type 2 diabetes drug Invokana (canagliflozin) in India. The drug will be marketed at INR 51 per tablet (dosage unknown), or INR 1,530 for a 30-day course of treatment. Invokana works to prevent the re-absorption of glucose by the kidneys, allowing glucose to be excreted in urine, thereby potentially improving glycaemic control.

Johnson & Johnson Announces Unaudited Consolidated Earnings Results for the First Quarter Ended March 29, 2015; Updates Earnings Guidance for the Full Year of 2015

Johnson & Johnson announced unaudited consolidated earnings results for the first quarter ended March 29, 2015. For the quarter, the company announced sales to customers of $17,374 million compared to $18,115 million for the same period a year ago. Earnings before provision for taxes on income was $5,575 million compared to $5,424 million for the same period a year ago. Net earnings were $4,320 million compared to $4,727 million for the same period a year ago. Net earnings per share (diluted) were $1.53 compared to $1.64 for the same period a year ago. Adjusted earnings before provision for taxes on income was $5,630 million compared to $5,928 million for the same period a year ago. Adjusted net earnings were $4,418 million compared to $4,693 million for the same period a year ago. Adjusted net earnings per share (diluted) were $1.56 compared to $1.63 for the same period a year ago. The company updated earnings guidance for the full year of 2015. The company updated its adjusted earnings guidance for full-year 2015 to $6.04 - $6.19 per share reflecting further negative foreign currency movements. The company's guidance excludes the impact of after-tax intangible amortization expense and special items. The company expects an effective tax rate for 2015, excluding special items to be approximately 21% to 22%. The company announced that it is comfortable with adjusted EPS guidance in a range between $6.64 to $6.79 per share on a constant currency basis, reflecting an operational or constant currency growth rate of 4% to 6%. This is higher than the company’s previous guidance by $0.10 per share, reflecting some operational improvements and the higher other income and expense it noted earlier, partially offset by higher tax rate. Operational sales growth is expected to range between 1% and 2%, the company is pleased to note that when excluding the impact of acquisitions and divestitures and the impact of hepatitis C products, its operational sales growth at the midpoint of its guidance is approximately 6% for the full year 2015 as compared to 5% for all of 2014.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
JNJ:CB $0.00 COP 0.00

JNJ Competitors

Market data is delayed at least 15 minutes.

Company Last Change
General Electric Co $27.31 USD +0.23
International Business Machines Corp $173.67 USD +2.38
Novartis AG SFr.96.65 CHF -0.05
Roche Holding AG SFr.269.40 CHF +1.00
Procter & Gamble Co/The $80.29 USD +0.78
View Industry Companies
 

Industry Analysis

JNJ

Industry Average

Valuation JNJ Industry Range
Price/Earnings 17.5x
Price/Sales 3.8x
Price/Book -- Not Meaningful
Price/Cash Flow 17.5x
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact JOHNSON & JOHNSON, please visit www.jnj.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.